8-K: Vera Therapeutics Announces Positive 72-Week Data for Atacicept in IgA Nephropathy Trial

Vera Therapeutics reported positive 72-week data from its Phase 2b ORIGIN trial, showing atacicept's potential as a disease-modifying treatment for IgA nephropathy.

Summary

• Vera Therapeutics announced positive 72-week data from the open label extension of its Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy (IgAN).
• The trial showed a 62% reduction in Gd-IgA1, a reduction in hematuria to 19%, and a 48% reduction in urine protein to creatinine ratio (UPCR) in participants treated with atacicept for 72 weeks.
• Participants also showed stable estimated glomerular filtration rate (eGFR) with no change from baseline at 72 weeks, while eGFR typically declines by approximately 1 mL/min/1.73m2 per year in the general population.
• Patients who switched from placebo to atacicept showed similar improvements, including a 59% reduction in Gd-IgA1, a reduction in hematuria to 41%, and a 47% reduction in UPCR.
• The safety data from the open label extension were consistent with the randomized period, indicating that atacicept was generally well-tolerated.
• The company is advancing the Phase 3 ORIGIN 3 clinical trial, which is expected to be fully enrolled in the second half of 2024.
• Topline results from the Phase 3 trial are expected in the first half of 2025, with a potential biologics license application (BLA) submission in the second half of 2025 and a projected commercial launch in 2026.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, indicating a strong potential for atacicept as a disease-modifying therapy for IgAN. The data is compelling and the company is progressing well with its Phase 3 trial, suggesting a high likelihood of success.

Positives

• Atacicept showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR over 72 weeks.
• The drug demonstrated eGFR stabilization, which is a key indicator of kidney function, over the 72-week period.
• Patients who switched from placebo to atacicept experienced similar benefits to those who were originally on the drug.
• The safety profile of atacicept was consistent and well-tolerated in the open label extension.
• The company has a strong financial position with approximately $185 million in pro forma cash to fund operations to 2026.

Risks

• The regulatory approval process carries inherent risks and uncertainties.
• Results from earlier clinical trials may not be replicated in later trials.
• Preliminary results may not accurately predict topline results.
• The company faces general business risks, macroeconomic and geopolitical uncertainties.
• There is a risk that the company may not be able to execute its strategy for its programs.

Future Outlook

The company expects to complete enrollment of the Phase 3 ORIGIN 3 trial in the second half of 2024, report topline results in the first half of 2025, and submit a BLA in the second half of 2025, with a potential commercial launch in 2026.

Management Comments

• Richard Lafayette, M.D., stated that the data from the OLE show that switching to atacicept halted the eGFR decline seen in participants initially treated with placebo.
• Marshall Fordyce, M.D., CEO of Vera Therapeutics, believes these data further support the belief that atacicept has the disruptive potential to stand out as a disease-modifying treatment for patients with IgAN.

Industry Context

The announcement is significant as it provides further evidence for atacicept's potential as a disease-modifying therapy for IgAN, a condition with high unmet medical need. The results position Vera Therapeutics as a potential leader in the IgAN treatment landscape.

Comparison to Industry Standards

• The 72-week data for atacicept shows a stabilization of eGFR, which is a significant improvement compared to the typical decline seen in IgAN patients and the general population.
• Other therapies such as Tarpeyo and Filspari have shown some benefit in reducing proteinuria, but atacicept's dual inhibition mechanism and eGFR stabilization suggest a potentially superior disease-modifying effect.
• Sibeprenlimab, Zigakibart, Telitacicept and Povetacicept are other therapies in development for IgAN, but atacicept has shown a strong profile with a 62% reduction in Gd-IgA1 at 72 weeks and a 48% reduction in UPCR.
• Atacicept is administered via a small volume subcutaneous injection once weekly, which is a more convenient method compared to some other therapies that require intravenous infusions or larger injection volumes.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and the potential for a successful product launch.
• Patients with IgAN stand to benefit from a new treatment option that has shown promising results in modifying the disease.
• Employees of Vera Therapeutics may experience increased job security and opportunities due to the company's progress.
• The medical community will gain a new tool for managing IgAN, potentially improving patient outcomes.

Next Steps

• The company will continue to advance the ongoing pivotal Phase 3 clinical trial of atacicept.
• The company plans to present ongoing data from the Phase 2b trial later in 2024.
• The company expects to submit a biologics license application (BLA) for atacicept in IgAN to the U.S. Food and Drug Administration in the second half of 2025.
• The company anticipates a commercial launch of atacicept in 2026, if approved.

Key Dates

Keywords

Atacicept, IgA Nephropathy, IgAN, Kidney Disease, Clinical Trial, Phase 2b, Phase 3, eGFR, Proteinuria, Gd-IgA1, B-cell modulation, Autoimmune Disease